May 2026 Research Update

Together, these papers show that Castleman disease can be hard to recognize because symptoms and scans can resemble other illnesses (including certain nerve disorders, lung problems, or infections). Across the case reports, the diagnosis became clearer only after tissue biopsy and a broader, whole-body evaluation, rather than relying on one organ or one lab value alone. One separate study focused on improving testing for a virus linked to some Castleman disease cases by validating a sensitive blood test for HHV-8 (human herpesvirus 8).

In one patient with progressive numbness that initially fit chronic inflammatory demyelinating polyneuropathy (CIDP), the final diagnosis changed to POEMS syndrome after blood testing found a monoclonal IgA-lambda protein and a lymph node biopsy showed changes of plasma cell type idiopathic multicentric Castleman disease (iMCD), one of the findings that supported POEMS. The report also described multiple nerve-related antibodies in blood and spinal fluid, highlighting how nerve symptoms can overlap between CIDP and POEMS syndrome linked to iMCD. [1]

In a second report, a teenager with fever, widespread swollen lymph nodes, swelling, and breathing symptoms was first thought to have disseminated tuberculosis, but lymph node histology instead supported multicentric Castleman disease. The authors emphasized that biopsy can be central when infections and Castleman disease look similar based on symptoms and basic imaging. [2]

A third case showed that lung imaging changes may not always identify the main problem: a man with iMCD with TAFRO syndrome had ground-glass changes on chest CT, yet a bronchoscopic lung biopsy did not show inflammation. Bone marrow and lymph node biopsies were needed to confirm iMCD-TAFRO, suggesting that when symptoms are systemic, testing only one affected organ can miss the underlying diagnosis. [3]

Another report highlighted how certain tests can be confusing in specific situations: a man being treated with local (eye) anti-VEGF therapy developed one-sided optic disc swelling and was later diagnosed with POEMS syndrome with plasma cell variant Castleman disease on lymph node biopsy and imaging. His systemic VEGF blood level was low, which the authors thought could be due to the eye treatment, potentially making a POEMS workup harder to interpret if VEGF is expected to be high. [4]

Beyond case reports, one study developed and validated a whole-blood quantitative PCR test to measure HHV-8 DNA, targeting the ORF26 region. In this single-center validation, the test showed 100% agreement with a composite clinical standard, and higher viral loads tended to appear in certain HHV-8 related diseases, including multicentric Castleman disease in people with HIV; in a small set of patients with follow-up samples, viral load declined alongside clinical improvement. [5]

For patients and caregivers, this set of papers mainly reinforces that diagnosis often depends on putting multiple pieces together: symptoms, imaging across the body, blood tests (including proteins and sometimes virus testing), and especially lymph node or other tissue biopsy. It also shows why results can be hard to interpret when conditions overlap (for example, nerve problems that look like CIDP, infections that resemble Castleman disease, or treatments that may affect a lab marker like VEGF). The HHV-8 blood test study is most relevant as background on how laboratories may measure HHV-8 more consistently, but it does not by itself answer which individual patients should be tested or how results should be used.

Across this month's papers, the overall pattern was that treatments aimed at the immune signals believed to drive multicentric Castleman disease were repeatedly described as helpful, although most evidence here came from single-patient case reports. A clinical practice guideline for idiopathic multicentric Castleman disease (iMCD) emphasized interleukin-6 as a key driver and placed interleukin-6 blocking therapy first, with rituximab-based options as later treatment. [6]

The guideline recommended siltuximab as first-line therapy for iMCD and described rituximab-based regimens as second-line therapy, reflecting the central role of interleukin-6 in many patients while noting that the overall disease biology is still not fully understood. Because this was a guideline rather than a single trial report, it summarizes broader clinical experience rather than presenting new outcome numbers in the abstract. [6]

In TAFRO syndrome (a rare subtype of iMCD), one 43-year-old man treated with high-dose corticosteroids plus siltuximab had gradual improvement, including reduced whole-body swelling and fluid overload, partial kidney recovery, and improved blood counts. This report also described intensive supportive care during severe illness, including intensive care and temporary kidney support. [7]

Another single-patient report described a 75-year-old man with TAFRO-type iMCD who received siltuximab alone (without corticosteroids due to bleeding from a peptic ulcer), with the authors reporting significant clinical benefit. This case suggests that, in at least one person, interleukin-6 blockade was reported as effective even when standard combination approaches were not used. [8]

A separate case report described Castleman disease progressing from unicentric to multicentric disease, where subcutaneous tocilizumab (another medicine that blocks the interleukin-6 pathway) was reported to be effective. Because this is a single case, it cannot show how often this approach works or which patients are most likely to benefit. [9]

For HIV-associated multicentric Castleman disease, one 75-year-old man relapsed around the time of SARS-CoV-2 (COVID-19) infection, with relapse confirmed on lymph node biopsy, and he improved markedly after rituximab. The authors raised the possibility that COVID-19 could have contributed to reactivation of HHV-8 (the virus linked to this form of disease), but this was a temporal link in one patient and cannot prove cause and effect. [10]

For patients and caregivers, these papers mainly reinforce which medicine types are commonly used for multicentric Castleman disease and how choices may differ by subtype (idiopathic/TAFRO versus HIV-associated). The guideline provides the most practice-oriented summary (interleukin-6 blocking therapy and, if needed, rituximab-based regimens), while the case reports add real-world examples that improvement can include swelling, blood counts, and kidney function, but they cannot predict what will happen for most people. Uncertainty remains because several reports describe only one patient, and safety details and longer-term outcomes were not consistently reported in these summaries. [6] [7] [8] [9] [10]

Across these reports, surgery was used when Castleman disease appeared to be limited to one area (unicentric) and imaging could not reliably distinguish it from other growths such as kidney or pancreatic tumors. In each case, removing the mass served two roles: it treated the localized mass and allowed a definite diagnosis through tissue testing. Because these are case reports, they describe individual outcomes and cannot predict what will happen for everyone. [11] [12] [13]

Two patients had abdominal masses removed surgically, including one retroperitoneal mass taken out laparoscopically, with pathology confirming unicentric Castleman disease. One of these patients was reported to be disease-free at 2 years without additional therapy, while the other had an uneventful recovery and continued follow-up. [12] [11]

One patient had a mass in a kidney that looked like kidney cancer on scans, leading to laparoscopic kidney removal; tissue testing afterward showed hyaline vascular Castleman disease. Symptoms resolved after surgery and recovery was described as uneventful. [13]

For patients and caregivers, these papers provide background on why surgery may come up in unicentric Castleman disease: a single mass in locations like the retroperitoneum or kidney may be removed both to establish the diagnosis and to address the localized problem. What remains uncertain is how often these outcomes apply more broadly, since the evidence here comes from three individual cases and does not compare surgery with other approaches. [11] [12] [13]

Across two small retrospective reports, outcomes and complications differed mainly by whether Castleman disease was unicentric (one area) or multicentric (many areas). Unicentric disease generally looked less system-wide and was most often managed with surgery, while multicentric disease more often had body-wide symptoms and abnormal blood markers and needed medication-based treatment. The adult report described improvement in all 13 patients, with no recurrences reported during a median follow-up of 12 months. The pediatric study also explored factors that might relate to prognosis, but its small sample means those potential predictors need confirmation. [14] [15]

In a pediatric cohort of 30 patients, unicentric disease was linked to fewer systemic symptoms and less enlargement of the liver and spleen than multicentric disease. Children with unicentric disease also tended to have higher hemoglobin and albumin, while multicentric disease had higher inflammation markers and platelet counts; these differences suggest multicentric disease may place more strain on the body. Exploratory prediction models in this small dataset suggested fatigue and certain blood measures might help estimate outcomes, but these signals need validation in larger groups. [14]

In an adult case series of 13 patients, surgery was mainly used for unicentric disease, while multicentric disease was managed with medication, observation, or combinations. The authors reported that all patients improved and there were no recurrences during a median follow-up of 12 months, although the series was small and follow-up was relatively short. Some multicentric cases included fluid around organs (serous cavity effusions) and kidney involvement, showing that complications can extend beyond lymph nodes in some patients. [15]

For patients and caregivers, these studies mainly reinforce that the unicentric versus multicentric pattern can shape what problems show up (local mass versus more whole-body symptoms and organ involvement) and what treatments are commonly used. The improvement reported here is short-term and comes from small, single-center retrospective studies, so it is best viewed as background context rather than a firm prediction for any individual. What remains uncertain is which blood markers or symptoms reliably forecast longer-term outcomes across different hospitals and patient groups, especially in children. [14] [15]

One multicenter retrospective real-world study looked at follicular dendritic cell sarcoma (a rare tumor that can overlap with Castleman-type lymph node changes) and found that outcomes depended strongly on where the tumor occurred and whether it was linked to a hyaline-vascular Castleman pattern. Abdominal cases had more recurrences or spread and shorter time without worsening than non-abdominal cases, while a different EBV-positive inflammatory subtype showed a distinct pattern and no hyaline-vascular Castleman overlap. This study was not about typical Castleman disease outcomes directly, but it helps explain one pathway of serious complications in a subset of patients with related tissue changes. [16]

Among follicular dendritic cell sarcoma cases, the intra-abdominal group had a high recurrence or metastasis rate (81.3%, 13/16) and a lower median overall survival (70 months) than extra-abdominal cases (150 months). The study also reported that half of intra-abdominal cases occurred together with hyaline-vascular Castleman disease changes, compared with 11.1% outside the abdomen and 0% in the EBV-positive inflammatory subtype. The authors described a possible stepwise tissue spectrum from hyaline-vascular Castleman changes to abnormal follicular dendritic cells and then sarcoma, but this remains observational. [16]

This research matters mainly as context about rare but serious complications that can occur in a minority of situations where Castleman-type tissue patterns and certain tumors overlap, especially in the abdomen. It does not mean most people with Castleman disease will develop a sarcoma, and the study does not provide a way to predict who might be affected. What is still uncertain is how often this proposed progression happens in other regions and health systems, since the data come from retrospective records with some loss to follow-up. [16]